Stay updated on LN-145 + Pembrolizumab in Transitional Cell Cancer Clinical Trial
Sign up to get notified when there's something new on the LN-145 + Pembrolizumab in Transitional Cell Cancer Clinical Trial page.

Latest updates to the LN-145 + Pembrolizumab in Transitional Cell Cancer Clinical Trial page
- Check7 days agoNo Change Detected
- Check13 days agoChange DetectedUpdated the page to Revision 3.4.2. The government funding lapse notice and the prior Revision: v3.4.1 entry were removed.SummaryDifference0.4%

- Check20 days agoChange DetectedAdded a site-wide notice about government funding lapse and NIH open status. Updated the site revision from v3.4.0 to v3.4.1.SummaryDifference0.4%

- Check28 days agoChange DetectedUI and metadata changes include displaying the glossary option, adding 'No FEAR Act Data', and updating the Revision to v3.4.0, while removing the older items 'Last Update Submitted that met QC Criteria', 'No FEAR Act data', and the older Revision v3.3.4. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check42 days agoChange DetectedFooter revision updated to v3.3.4 (replacing v3.3.3); no changes to study content or page functionality were detected. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check63 days agoChange DetectedAdded a Locations section showing New York as a study site (Buffalo, NY). Removed the separate New York Locations reference and the HHS Vulnerability Disclosure entry, and updated the page revision to v3.3.3.SummaryDifference0.2%

- Check91 days agoChange DetectedPage revision updated from v3.2.0 to v3.3.2; no substantive content changes observed in the study details page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to LN-145 + Pembrolizumab in Transitional Cell Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the LN-145 + Pembrolizumab in Transitional Cell Cancer Clinical Trial page.